Drug intelligence / Profile preview

CR-0305

Development stage: Preclinical
Lead developer: Coeurative
Modality: Small Molecules
Administration: Oral

Overview

CR-0305 is a preclinical-stage small molecule nitric oxide (NO) donor being developed by Coeurative for the treatment of refractory angina and coronary artery disease. Described as having a 'Breakthrough Dual-Action Mechanism,' the drug promotes vascular smooth muscle relaxation and coronary vasodilation. In ex vivo human coronary artery studies, CR-0305 demonstrated 23-fold greater vasodilatory potency than isosorbide mononitrate (ISMN), with an IC50 of 3.0 µM compared to 67.8 µM for ISMN. The program is currently in preclinical development, with a first-in-human (FIH) study planned for 2027.

Targets

PLpro (Papain-like protease)sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on CR-0305.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CR-0305.

Explore the full profile